Atrium Therapeutics, Inc. (RNA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.68-0.46%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RNA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -56.6% |
| Our one-year growth estimate | diamond | -84.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 27.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
RNA — litigation filed
Dated 2026-11-02
Other Events. On November 2, 2026, the Company announced that it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for the potential treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (“PRKAG2”) syndrome during HCMS at the American Heart Association Scientific Sessions 2026, taking place on November 6, 2026, in Chicago, Illinois. The nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2 syndrome deve…
Why it matters: Early results can show whether ATR 1072 is safe and changes heart measures in PRKAG2 patients. Poor results would weaken the lead program.
Watch forInitial data arrive in the second half of 2027. They show acceptable safety and better heart structure or function.
Also watch forInitial data show serious safety issues or no improvement in heart structure or function. Or data miss the stated 2027 window.
Why it matters: A named candidate would show that Atrium is widening its pipeline beyond ATR 1072 and ATR 1086. No selection would delay that expansion.
Supportive ifIn 2027, Atrium names a new candidate from its two research programs for rare heart diseases.
Worry ifAtrium reports no candidate choice by the end of 2027, or ends both research programs without naming one.
Why it matters: The October financing adds cash, while new shares and warrants can dilute existing owners. Closing terms and cash use will show the net effect.
Watch forAtrium reports that the offering closed and raised about $50 million gross. It later reports cash use that supports planned work through mid-2028.
Also watch forAtrium reports that the offering did not close or raised far less than about $50 million gross. Or it later cuts planned work due to cash needs.
Why it matters: A filing would advance the second named drug program toward human testing. A missed filing would leave the pipeline more dependent on ATR 1072.
Supportive ifAtrium files an IND application for ATR 1086 during 2027, as stated in its timeline.
Worry ifAtrium reports that the ATR 1086 IND filing has slipped beyond 2027 or that IND-enabling work has stopped.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$172 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $566 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,399 loss on $10,000 · 54.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.